Immunotherapy of colorectal cancer: new perspectives after a long path

被引：17

作者：

Correale, Pierpaolo ^{[1
]}

Botta, Cirino ^{[2
,3
]}

Ciliberto, Domenico ^{[2
,3
]}

Pastina, Pierpaolo ^{[1
]}

Ingargiola, Rossana ^{[2
,3
]}

Zappavigna, Silvia ^{[4
]}

Tassone, Pierfrancesco ^{[2
,3
]}

Pirtoli, Luigi ^{[1
]}

Caraglia, Michele ^{[4
]}

Tagliaferri, Pierosandro ^{[2
,3
]}

机构：

[1] Univ Siena, Sch Med, Dept Med Surg & Neurosci, Unit Radiotherapy, Viale Bracci 11, I-53100 Siena, Italy

[2] Magna Grecia Univ, AUO Materdomini, Med Oncol Unit, Catanzaro, Italy

[3] Magna Grecia Univ, AUO Materdomini, Med Oncol Unit, Catanzaro, Italy

[4] Univ Naples 2, Dept Biochem Biophys & Gen Pathol, Naples, Italy

来源：

IMMUNOTHERAPY | 2016年 / 8卷 / 11期

关键词：

cancer vaccine; carcinoembryonic antigen; chemotherapy; colorectal cancer; immune-modulating strategies; thymidylate synthase; ACTIVE SPECIFIC IMMUNOTHERAPY; COLONY-STIMULATING FACTOR; TUMOR-CELL VACCINE; PHASE-I TRIAL; ANTITUMOR-ACTIVITY; MONOCLONAL-ANTIBODIES; PROGRAMMED DEATH-1; IMMUNE-RESPONSES; ANTIGEN; 5T4; STAGE-II;

D O I：

10.2217/imt-2016-0089

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Although significant therapeutic improvement has been achieved in the last 10 years, the survival of metastatic colorectal cancer patients remains in a range of 28 to 30 months. Presently, systemic treatment includes combination chemotherapy with oxaliplatin and/or irinotecan together with a backbone of 5-fluorouracil/levofolinate, alone or in combination with monoclonal antibodies to VEGFA (bevacizumab) or EGF receptor (cetuximab and panitumumab). The recent rise of immune checkpoint inhibitors in the therapeutic scenario has renewed scientific interest in the investigation of immunotherapy in metastatic colorectal cancer patients. According to our experience and view, here, we review the immunological strategies investigated for the treatment of this disease, including the use of tumor target-specific cancer vaccines, chemo-immunotherapy and immune checkpoint inhibitors.

引用

页码：1281 / 1292

页数：12

共 81 条

[1] Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy [J].

Adkins, Irena ;

Fucikova, Jitka ;

Garg, Abhishek D. ;

Agostinis, Patrizia ;

Spisek, Radek .

ONCOIMMUNOLOGY, 2014, 3 (12) :1-12

[2] The potential role of immunotherapy to treat colorectal cancer [J].

Amin, Manik ;

Lockhart, Albert Craig .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (03) :329-344

[3]

[Anonymous], GLOBOCAN

[4] A Randomized Trial of Ex vivo CD40L Activation of a Dendritic Cell Vaccine in Colorectal Cancer Patients: Tumor-Specific Immune Responses Are Associated with Improved Survival [J].

Barth, Richard J., Jr. ;

Fisher, Dawn A. ;

Wallace, Paul K. ;

Channon, Jacqueline Y. ;

Noelle, Randolph J. ;

Gui, Jiang ;

Ernstoff, Marc S. .

CLINICAL CANCER RESEARCH, 2010, 16 (22) :5548-5556

[5] CD4+ T-cell help amplifies innate signals for primary CD8+ T-cell immunity [J].

Bedoui, Sammy ;

Heath, William R. ;

Mueller, Scott N. .

IMMUNOLOGICAL REVIEWS, 2016, 272 (01) :52-64

[6] Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis [J].

Bertrand, Anne ;

Kostine, Marie ;

Barnetche, Thomas ;

Truchetet, Marie-Elise ;

Schaeverbeke, Thierry .

BMC MEDICINE, 2015, 13

[7] The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation [J].

Blank, Christian U. .

CURRENT OPINION IN ONCOLOGY, 2014, 26 (02) :204-214

[8] ESMO ECCO 2015: The highlights of immunotherapy and targeted therapies [J].

Bonnet, Clement ;

Beinse, Guillaume ;

Cabel, Luc ;

Cochereau, Delphine ;

Lavaud, Pernelle ;

Rochefort, Pauline ;

Tabouret, Emeline ;

Turpin, Anthony ;

Verlingue, Loic ;

Vicier, Cecile ;

Massard, Christophe .

BULLETIN DU CANCER, 2016, 103 (06) :594-603

[9] The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response [J].

Botta, C. ;

Misso, G. ;

Martino, E. C. ;

Pirtoli, L. ;

Cusi, M. G. ;

Tassone, P. ;

Tagliaferri, P. ;

Caraglia, M. ;

Correale, P. .

CELL DEATH & DISEASE, 2016, 7 :e2299-e2299

[10] Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients [J].

Botta, Cirino ;

Bestoso, Elena ;

Apollinari, Serena ;

Cusi, Maria Grazia ;

Pastina, Pierpaolo ;

Abbruzzese, Alberto ;

Sperlongano, Pasquale ;

Misso, Gabriella ;

Caraglia, Michele ;

Tassone, Pierfrancesco ;

Tagliaferri, Pierosandro ;

Correale, Pierpaolo .

JOURNAL OF IMMUNOTHERAPY, 2012, 35 (05) :440-447

← 1 2 3 4 5 6 7 8 9 →